Research progress of oxazolidinone antibiotics
10.16438/j.0513-4870.2022-0685
- VernacularTitle:噁唑烷酮类抗菌药物研究进展
- Author:
Yu-hua HU
;
Xin-tong ZHAO
;
Tian-lei LI
;
Song WU
;
Wen-xuan ZHANG
- Publication Type:Research Article
- Keywords:
resistant bacterial infection;
oxazolidinone antibiotics;
structural optimization;
structure-activity relationship;
ruggability evaluation
- From:
Acta Pharmaceutica Sinica
2022;57(11):3276-3291
- CountryChina
- Language:Chinese
-
Abstract:
Linezolid is the first oxazolidinone antibacterial drug approved by the FDA, which can effectively treat various gram-positive bacterial infections, including blood infections, skin and soft tissue infections, community and hospital-acquired pneumonia. It has become one of the most commonly used antibiotics in clinical. In addition to the recently launched tedizolid phosphate (TR701) and contezolid (MRX-I), several oxazolidinone anti-infective candidates are currently under clinical research. This review briefly introduces the oxazolidinone antibiotics that have been marketed and are in clinical trials, and recent progress on the structure optimization of oxazolidinone drugs is also summarized.
